Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 27.53B, Biogen(BIIB) trades at $187.62. The stock has a price-to-earnings ratio of 17.11.
As of 2026-01-10, Biogen(BIIB) stock has fluctuated between $186.49 and $190.20. The current price stands at $187.62, placing the stock +0.6% above today's low and -1.4% off the high.
The Biogen(BIIB)'s current trading volume is 1.4M, compared to an average daily volume of 1.32M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
BIIB News
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview This Phase 1 Biogen study, officially t...
Biogen (BIIB) is back in focus after Chinese regulators accepted the Biologics License Application for a subcutaneous version of LEQEMBI, highlighting a potenti...
Truist raised the firm’s price target on Biogen (BIIB) to $190 from $142 and keeps a Hold rating on the shares. The firm updated its model, but tells investors...
Analyst ratings
50%
of 36 ratingsMore BIIB News
In a report released today, Michael Yee from UBS maintained a Hold rating on Biogen, with a price target of $185.00. Claim 70% Off TipRanks Premium Unlock hedge...
Biogen and Eisai previously announced that China’s National Medical Products Administration accepted their Biologics License Application for a subcutaneous, onc...
Eisai (ESALY) and Biogen (BIIB) announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI, an anti-amyloid beta protofibril a...